Through investigación conjunta by RudaCure's technical team and Gachon University Gil Hospital, a study on MMP9 — which can be used as a biomarker in enfermedad de ojo seco pacientes — was published in an academic journal.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910104/